Literature DB >> 27346141

Prognostic significance of neutrophil to lymphocyte ratio in patients with gallbladder carcinoma.

Lingqiang Zhang1, Ruitao Wang1, Wei Chen1, Xinsen Xu1, Shunbing Dong1, Haining Fan2, Chang Liu3.   

Abstract

BACKGROUND: Numerous literature suggest that the preoperative neutrophil to lymphocyte ratio (NLR) is correlated to the prognosis of various cancers. However, the prognostic significance of NLR in gallbladder carcinoma (GBC) remains to be determined.
METHODS: Data from 316 GBC patients with surgical treatment were reviewed retrospectively. A receiver operating characteristic (ROC) curve was performed to determine an optimal cut-off value for NLR. The Kaplan-Meier method and Cox regression proportional hazard model were performed to evaluate prognostic factors.
RESULTS: The optimal cut-off point for NLR was 2.61 according to the ROC curve. According to the univariable analysis, NLR, differentiation and TNM stage were associated with GBC prognosis. GBC patients with NLR > 2.61 have worsened 5-year overall survival (OS) compared to patients with NLR ≤ 2.61 (P < 0.001). Multiple analyses indicated that NLR (hazard ratio (HR) 1.65; 95 percent confidence interval (95% CI) 1.25-2.17), differentiation (HR 1.25; 95% CI 0.97-1.62) and TNM stage (HR 3.79; 95% CI 2.09-6.87) were independent prognostic factors for GBC. GBC patients in stage III/IV, NLR > 2.61 exhibited worse OS compared to patients with NLR ≤ 2.61 (P < 0.05). A prognostic evaluation model based on the independent prognostic factors was established.
CONCLUSION: NLR is associated with GBC prognosis and is a potential prognostic marker for GBC, not only preoperatively but also postoperatively.
Copyright © 2016 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27346141      PMCID: PMC4925805          DOI: 10.1016/j.hpb.2016.03.608

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  33 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma.

Authors:  Karim J Halazun; Mark A Hardy; Abbas A Rana; David C Woodland; Elijah J Luyten; Suhari Mahadev; Piotr Witkowski; Abbey B Siegel; Robert S Brown; Jean C Emond
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

3.  Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer.

Authors:  M G McNamara; A J Templeton; M Maganti; T Walter; A M Horgan; L McKeever; T Min; E Amir; J J Knox
Journal:  Eur J Cancer       Date:  2014-03-11       Impact factor: 9.162

4.  Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes.

Authors:  H T Petrie; L W Klassen; H D Kay
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

5.  Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma.

Authors:  Y Zhang; C Jiang; J Li; J Sun; X Qu
Journal:  Clin Transl Oncol       Date:  2015-06-16       Impact factor: 3.405

6.  Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study.

Authors:  Yoshihito Imai; Yoshitsugu Kubota; Shin Yamamoto; Kazuyuki Tsuji; Masaaki Shimatani; Nobuyuki Shibatani; Shoichiroh Takamido; Masanori Matsushita; Kazuichi Okazaki
Journal:  J Gastroenterol Hepatol       Date:  2005-02       Impact factor: 4.029

7.  Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma.

Authors:  D Gomez; S Farid; H Z Malik; A L Young; G J Toogood; J P A Lodge; K R Prasad
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

8.  Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma.

Authors:  Decai Yu; Xitai Sun; Yudong Qiu; Jianxing Zhou; Yafu Wu; Lingyuan Zhuang; Jun Chen; Yitao Ding
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

9.  A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation.

Authors:  Guo-Ying Wang; Yang Yang; Hua Li; Jian Zhang; Nan Jiang; Min-Ru Li; Huan-Bing Zhu; Qi Zhang; Gui-Hua Chen
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

10.  The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer.

Authors:  M H Kang; S-I Go; H-N Song; A Lee; S-H Kim; J-H Kang; B-K Jeong; K M Kang; H Ling; G-W Lee
Journal:  Br J Cancer       Date:  2014-06-12       Impact factor: 7.640

View more
  12 in total

1.  Low serum C3 level, high neutrophil-lymphocyte-ratio, and high platelet-lymphocyte-ratio all predicted poor long-term renal survivals in biopsy-confirmed idiopathic membranous nephropathy.

Authors:  Shang-Feng Tsai; Ming-Ju Wu; Cheng-Hsu Chen
Journal:  Sci Rep       Date:  2019-04-17       Impact factor: 4.379

2.  Preoperative platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as predictors of clinical outcome in patients with gallbladder cancer.

Authors:  Sha Zhu; Jing Yang; Xiwei Cui; Yunuo Zhao; Zhihang Tao; Fan Xia; Linyan Chen; Juan Huang; Xuelei Ma
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

3.  Combination of CA19-9 and the Neutrophil-to-Lymphocyte Ratio for the Differential Diagnosis of Gallbladder Carcinoma.

Authors:  Zeyang Chen; Zining Liu; Yuyang Zhang; Pengyuan Wang; Hongqiao Gao
Journal:  Cancer Manag Res       Date:  2020-06-12       Impact factor: 3.989

4.  Independent effect of postoperative neutrophil-to-lymphocyte ratio on the survival of pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy and its nomogram-based prediction.

Authors:  Ning Pu; Hanlin Yin; Guochao Zhao; Abulimiti Nuerxiati; Dansong Wang; Xuefeng Xu; Tiantao Kuang; Dayong Jin; Wenhui Lou; Wenchuan Wu
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

5.  Prognostic Value Of Preoperative Systemic Inflammatory Biomarkers In Patients With Gallbladder Cancer And The Establishment Of A Nomogram.

Authors:  Yan Deng; Feng Zhang; Xiao Yu; Cheng-Long Huo; Zhen-Gang Sun; Shuai Wang
Journal:  Cancer Manag Res       Date:  2019-10-21       Impact factor: 3.989

6.  Single-cell RNA-seq reveals transcriptional landscape and intratumor heterogenicity in gallbladder cancer liver metastasis microenvironment.

Authors:  Yigang Zhang; Wen-Hua You; Xiangyu Li; Peng Wang; Bowen Sha; Yuan Liang; Jiannan Qiu; Jinren Zhou; Haoran Hu; Ling Lu
Journal:  Ann Transl Med       Date:  2021-05

7.  Prognostic Value of Peripheral Whole Blood Cell Counts Derived Indexes in Gallbladder Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Bowen Xu; Zhiqiang Chen; Jing Zhang; Jianhua Chang; Wei Zhao; Zhaoru Dong; Xuting Zhi; Tao Li
Journal:  Front Oncol       Date:  2021-06-28       Impact factor: 6.244

8.  Prognostic significance of combined preoperative fibrinogen and CA199 in gallbladder cancer patients.

Authors:  Wei-Yu Xu; Hao-Hai Zhang; Xiao-Bo Yang; Yi Bai; Jian-Zhen Lin; Jun-Yu Long; Jian-Ping Xiong; Jun-Wei Zhang; Xin-Ting Sang; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2018-04-07       Impact factor: 5.742

9.  The Impacts of Systemic Immune-Inflammation Index on Clinical Outcomes in Gallbladder Carcinoma.

Authors:  Lejia Sun; Yukai Jin; Wenmo Hu; Mengyuan Zhang; Bao Jin; Haifeng Xu; Shunda Du; Yiyao Xu; Haitao Zhao; Xin Lu; Xinting Sang; Shouxian Zhong; Huayu Yang; Yilei Mao
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244

10.  Diagnostic Value of Inflammatory Factors in Patients with Gallbladder Cancer, Dysplasia, and Cholecystitis.

Authors:  Sirin Kucuk; Soycan Mızrak
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.